For years, one of the biggest barriers to GLP-1 medications was the needle. Weekly injections are not for everyone — and for millions of people considering Ozempic or Wegovy, that alone was a dealbreaker. That just changed. In December 2025, the FDA approved the first ever oral GLP-1 medication for weight loss. Here is everything you need to know about the Wegovy pill — and what is coming next.
What Is the Wegovy Pill?
The Wegovy pill is a once-daily oral tablet containing semaglutide — the same active ingredient as the Wegovy injection and Ozempic. The FDA approved it on December 22, 2025, and it launched nationally in the US on January 5, 2026. This makes it the first oral GLP-1 receptor agonist approved specifically for weight management.
How Well Does It Work?
In the OASIS 4 clinical trial, people taking the Wegovy pill lost an average of 14% of their body weight over 64 weeks overall — with trial completers averaging 16.6% weight loss. The placebo group lost just 2%. That puts the pill in the same range as the injectable version of Wegovy, which showed 15% weight loss in its key trial. Meaningful results, without the needle.
How Is It Different From the Wegovy Injection?
Both contain semaglutide and work the same way — by mimicking the GLP-1 hormone to suppress appetite and slow digestion. The key differences are:
- The injection is taken once weekly. The pill is taken once daily.
- The pill must be taken on an empty stomach with a small amount of water, and you must wait 30 minutes before eating, drinking, or taking other medications — this is essential for proper absorption.
- A special delivery technology called SNAC protects the semaglutide molecule from breaking down in the stomach.
How Much Does It Cost?
⚠ Price Increase Alert
The 4mg dose is currently $149/month — but that price goes up to $199/month on April 15, 2026. If you are considering starting, now is a good time to lock in the lower price.
The Wegovy pill is significantly cheaper than the injection:
- Starting dose (1.5mg): $149/month for cash-pay patients
- 4mg dose: $149/month until April 15, 2026, then $199/month
- Higher doses (9mg and 25mg): $299/month
- With insurance: as little as $25/month
Compare that to the injectable Wegovy at $349/month for self-pay patients. Right now, the pill is the most affordable FDA-approved semaglutide option available.
Where Can You Get It?
The Wegovy pill is now available at over 70,000 US pharmacies, including CVS and Costco. Telehealth providers like Ro, LifeMD, Weight Watchers, and GoodRx also carry it. You need a prescription — get one through your doctor or a telehealth provider online.
What Are the Side Effects?
Side effects mirror those of the injectable version. Nausea, diarrhea, vomiting, and constipation are most common, especially in the first weeks. Most people find these improve as their body adjusts. The same strategies that help with injection nausea apply here — small meals, avoiding greasy foods, and staying hydrated.
Who Qualifies?
The Wegovy pill is approved for adults with:
- BMI of 30 or higher (obesity)
- BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
Doctors cannot prescribe it for people with type 1 diabetes or a personal or family history of medullary thyroid cancer.
What About Eli Lilly’s Pill?
Novo Nordisk will not be alone for long. Eli Lilly’s oral GLP-1 pill, orforglipron, has been submitted to the FDA and has a PDUFA decision date of April 10, 2026 — meaning an FDA ruling is expected within days. This is the most significant near-term development in the oral GLP-1 space.
And the data is compelling. In the ACHIEVE-3 trial — a direct head-to-head comparison published in The Lancet in February 2026 — orforglipron outperformed the oral Wegovy pill on both weight loss and blood sugar reduction (A1C). That is a significant result for a drug still awaiting final approval.
There is also a key practical difference: orforglipron has no food restriction. You can take it any time, with or without food. The Wegovy pill requires a 30-minute fasting window before and after, which some patients find inconvenient. For people with busy mornings, that distinction matters.
A separate trial, ATTAIN-MAINTAIN (data published December 2025), also showed orforglipron can be used as a maintenance option after stopping injectable GLP-1 therapy — an important use case as more patients cycle on and off injectables.
Wegovy Pill vs. Orforglipron: How Do They Compare?
| Wegovy Pill (Semaglutide) | Orforglipron (Eli Lilly) | |
|---|---|---|
| FDA Status | Approved (Dec 2025) | Decision expected Apr 10, 2026 |
| Weight Loss (trial) | 14% avg / 16.6% completers (OASIS 4) | Beat oral Wegovy head-to-head (ACHIEVE-3) |
| Food Restriction | 30 min empty stomach required | None — take any time |
| Dosing | Once daily | Once daily |
| Cash-Pay Price | $149–$299/month | TBD (not yet launched) |
| Active Ingredient | Semaglutide | Orforglipron (non-peptide) |
| Maintenance Use | Standard GLP-1 continuation | ATTAIN-MAINTAIN trial: effective after injectables |
🆕 What’s Coming Next
The oral GLP-1 space is moving fast. Here is what to watch in the next few weeks:
- April 10, 2026 — FDA decision on orforglipron (Eli Lilly). If approved, it will be the second oral GLP-1 for weight loss and the first without food timing restrictions.
- April 15, 2026 — Wegovy pill 4mg price increases from $149 to $199/month. If you are on the fence, the next two weeks are the cheapest entry point.
- Pricing competition — If orforglipron launches, expect Novo Nordisk to respond on price. Two competing oral GLP-1s is good news for patients.
We will update this page as new information becomes available. Bookmark it or subscribe to our newsletter to stay current.
The Wegovy pill is a genuine game changer for people who want the benefits of GLP-1 medication without weekly injections. At $149/month starting price, it is also the most accessible FDA-approved option yet — but that window is closing. If you are considering it, the fastest way to get a prescription is through a telehealth provider. Use our provider finder to compare your options and get started.
Medical Disclaimer
The content on this page is for informational and educational purposes only. It reflects general user experiences and publicly available clinical information about GLP-1 medications — not personal medical advice. Every person’s health situation is different. Before starting, adjusting, or stopping any medication or treatment, please consult a licensed healthcare provider or specialist who can evaluate your individual circumstances.